REG - CRISM Therapeutics - Result of AGM

CRISM TherapeuticsAnnouncement

26/08/2025 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250826:nRSZ7323Wa&default-theme=true

RNS Number : 7323W  CRISM Therapeutics Corporation  26 August 2025

 

26 August 2025

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

 

Result of AGM

 

CRISM Therapeutics (AIM: CRTX), the innovative UK drug delivery company
focused on the localised delivery of chemotherapy drugs, is pleased to confirm
that at the Company's Annual General Meeting held earlier today, all
resolutions were duly passed. Full details of the resolutions are set out in
the Notice of Annual General Meeting dated 4 August 2025 and available on the
Company's website at: https://www.crismtherapeutics.com/documents-and-notices
(https://www.crismtherapeutics.com/documents-and-notices)

 

The votes cast were as follows:

 

 Resolution  Votes for  Votes for %  Votes against  Votes against %  Abstentions
 1           5,094,571  100.00%      -              -                62
 2           5,094,049  99.99%       510            0.01%            74
 3           5,094,571  100.00%      -              -                62
 4           5,094,571  100.00%      -              -                62
 5           5,094,571  100.00%      -              -                62
 6           5,094,559  100.00%      -              -                74
 7           5,094,571  100.00%      -              -                62
 8           5,094,049  99.99%       572            0.01%            12
 9           5,094,049  99.99%       572            0.01%            12
 10          5,094,049  99.99%       572            0.01%            12
 11          5,094,213  99.99%       346            0.01%            74
 12          5,094,213  99.99%       408            0.01%            12
 13          5,094,213  99.99%       408            0.01%            12

 

 

-Ends-

 

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, CEO                Richard Morrison                  Mark Court / Jamie Hooper

 Chris McConville, CSO           Vadim Alexandre                   CRISM@buchanancomms.co.uk

                                 Adam Cowl
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

About CRISM Therapeutics Corporation

 

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

 

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the
blood brain barrier, which prevents other treatments from being able to reach
the tumour and be effective.

 

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

 

The Company's LEI is 213800XFW6MKVCHHPW88.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGUNRVRVRUWUAR